Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis

Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis

Aim: Patients with HER2-positive (HER2+) metastatic breast cancer (mBC) develop brain metastases (BM) in up to 30% of cases. Treatment of patients with BM can consist of local treatment (surgery and/or radiotherapy) and/or systemic treatment. We undertook a systematic review and meta-analysis to det...

Full description

Bibliographic Details
Main Authors: Inge M. Werter, Sharon Remmelzwaal, George L. Burchell, Tanja D. de Gruijl, Inge R. Konings, Hans J. van der Vliet, C. Willemien Menke-van der Houven van Oordt
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
breast cancer
brain metastases
HER2
lapatinib
trastuzumab-deruxtecan
tucatinib
Online Access:https://www.mdpi.com/2072-6694/14/22/5612

Internet

https://www.mdpi.com/2072-6694/14/22/5612

Similar Items